Neuralstem Announces Issuance of U.S. Patent Covering NSI-189
22 February 2017 - 11:03PM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused
on the development of central nervous system therapies based on its
neural stem cell technology, today announced that U.S. Patent No.
9572807 was issued by the United States Patent and Trademark Office
(USPTO) for NSI-189, the lead compound in Neuralstem's neurogenic
small molecule program in development for the treatment of major
depressive disorder. US 9,572,807 has claims to protocols for using
NSI-189 and related compounds for treatment of major depressive
disorder. Counterparts have been filed in Australia, Canada,
Europe, Japan, Singapore and South Korea. These patents will
expire in June 2035.
The new patent adds to the portfolio of over 20
U.S. and 120 foreign issued and pending patents that are owned or
licensed to Neuralstem in the field of regenerative medicine.
This includes U.S. Patent No. 9,540,611, issued on January 10, 2017
by the USPTO, covering the treatment of neurodegenerative diseases
using NSI-566, the company’s proprietary neural stem cell therapy
candidate.
“We are excited to be bringing forward
therapeutic options that could make a tremendous difference in the
lives of those who suffer from nervous system disorders and
conditions,” said Rich Daly, Chairman and CEO, Neuralstem.
“We will continue to aggressively establish a broad portfolio of
intellectual property to protect our research and development
efforts.”
About Neuralstem
Neuralstem’s patented technology enables the
commercial-scale production of multiple types of central nervous
system stem cells, which are being developed as potential therapies
for multiple central nervous system diseases and conditions.
Neuralstem’s technology enables the generation
of small molecule compounds by screening hippocampal stem cell
lines with its proprietary systematic chemical screening
process. The screening process has led to the discovery and
patenting of molecules that Neuralstem believes may stimulate the
brain’s capacity to generate new neurons, potentially reversing
pathophysiologies associated with certain central nervous system
(CNS) conditions.
The company has completed Phase 1a and 1b trials
evaluating NSI-189, a novel neurogenic small molecule product
candidate, for the treatment of major depressive disorder or MDD,
and is currently conducting a Phase 2 efficacy study for MDD.
Neuralstem’s stem cell therapy product
candidate, NSI-566, is a spinal cord-derived neural stem cell line.
Neuralstem is currently evaluating NSI-566 in three indications:
stroke, chronic spinal cord injury (cSCI), and Amyotrophic Lateral
Sclerosis (ALS).
Neuralstem is conducting a Phase 1 safety study
for the treatment of paralysis from chronic motor stroke at the
BaYi Brain Hospital in Beijing, China. In addition, NSI-566
is being evaluated in a Phase 1 safety study to treat paralysis due
to chronic spinal cord injury as well as a Phase 1 and Phase 2a
risk escalation, safety trials for ALS. Patients from all
three indications are currently in long-term observational
follow-up periods to continue to monitor safety and possible
therapeutic benefits.
Cautionary Statement Regarding Forward Looking
Information
This news release contains “forward-looking
statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek” or “will.” Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2015, and Form 10-Q for the nine months
ended September 30, 2016, filed with the Securities and Exchange
Commission (SEC), and in other reports filed with the SEC. We do
not assume any obligation to update any forward-looking
statements.
Danielle Spangler
Investor Relations
Neuralstem, Inc
301.366.1481
Lori Rosen
Public Relations
LDR Communications
917.553.6808
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2024 to May 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From May 2023 to May 2024